ADHD Assessment

ADHD Assessments at CADS (Child & Young Person)

CADS provides gold-standard private ADHD assessments, which are accepted by the NHS.

The ADHD assessment pathway includes:

Detailed developmental and clinical history
Structured ADHD interview (e.g. Young DIVA for children and adolescents)
Standardised rating scales (home, school, or self-report)
Direct observation and clinical interview
Multidisciplinary diagnostic review

CADS does not prescribe medication directly. If families wish to pursue medication via the NHS, private diagnostic reports are reviewed and it is at the GP’s discretion whether to refer onto the medication pathway. CADS also works in partnership with an external prescribing service for individuals aged 11 years and over, should private prescribing be preferred.

Dual Autism & ADHD Assessments

Dual Autism & ADHD Assessments (Child & Young Person)

Many children, young people, and adults present with overlapping autistic and ADHD traits. CADS offers combined autism and ADHD assessments, allowing both profiles to be explored within a single, integrated process.

A dual assessment includes:

Full autism assessment pathway (ADI-R, ADOS-2, school feedback)
ADHD-specific clinical interview (e.g. Young DIVA)
Additional observation and interview focusing on attention, regulation, and executive functioning
ADHD rating scales completed across settings
Multidisciplinary team diagnostic formulation

This approach reduces duplication, supports diagnostic clarity, and provides a joined-up understanding of strengths and support needs.

Fees & Timeframes

Fees

Autism Assessment: £2,000
ADHD Assessment: £1,300
Combined Autism & ADHD Assessment: £2,900

All fees include the full assessment process, feedback appointment, and detailed written diagnostic report.

Timeframes

We are currently booking assessments for February 2026, as referrals are received. Where possible, information gathering begins in advance, with final outcomes typically provided within 1–2 weeks of the final assessment session.